Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emerging Markets Earnings Roundup: Pfizer, Merck, AbbVie (Part 4)

This article was originally published in PharmAsia News

Executive Summary

AbbVie, Merck and Pfizer had contrasting numbers for their third quarter earnings. While AbbVie rode high on Humira, Merck faced tough conditions in China and Mexico. Pfizer outclassed most global companies in China, with a growth of 8%, which could have doubled had it not transferred some products to its Chinese JV with Hisun.

You may also be interested in...



Divestiture Possible For Merck’s Animal Health, Consumer Units; Januvia’s Sales Slide

The performance of Merck’s diabetes franchise came under scrutiny by analysts on an earnings call Oct 28, after the company reported sales of its number one drug fell 5% in the third quarter year on year. Top executives came closer than ever to saying they are inclined to divest non-core businesses, including animal health.

AbbVie Pipeline Offers Multiple Means Of Protection Against Humira Sales Erosion

Hepatitis C combo is just one of AbbVie’s late-stage pipeline prospects to cover losses from generic competition to TriCor/Trilipix and the threat of biosimilar competition to Humira. It also has ABT-199, daclizumab and elagolix in Phase III studies.

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel